Tech Company Inital Public Offerings
Aura Biosciences IPO
Aura Biosciences was acquired by . Shares were listed on 10/29/2021.
Transaction Overview
Company Name
Announced On
10/29/2021
Transaction Type
IPO
Amount
$75,600,000
Proceeds Purpose
We currently expect to use our net proceeds from this offering to advance our initial product candidate, to develop our platform, and for general corporate purposes, which may include the hiring of additional personnel, capital expenditures and the costs of operating as a public company.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
85 Bolton St.
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Website
Email Address
Overview
Aura Biosciences is developing a new class of therapies to target and selectively destroy tumor cells. Its lead program in ocular melanoma, developed under a CRADA with the National Cancer Institute (NCI), has been granted orphan drug status by the US Food and Drug Administration.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Elisabet de los Pinos
Chief Financial Officer
Julie Feder
Chief Medical Officer
Cadmus Rich
Browse more venture capital transactions:
Prev: 10/29/2021: Needed venture capital transaction
Next: 10/29/2021: Ontra venture capital transaction
Share this article
Where The Data Comes From
We record all VC transactions involving tech companies. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs